Wide Ranks

HOLX

Hologic, Inc.

79.44

Top Statistics
Market Cap 18 B Forward PE 16.86 Revenue Growth 4.50 %
Current Ratio 3.99 Trailing PE 23.93 Earnings Growth 111.60 %
Profit Margins 17.59 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 15.15 Enterprise / Revenue 4.72 Price To Sales Trailing12 Months 4.52
Profitability
Profit Margins 17.59 % Operating Margins 24.36 %
Balance Sheet
Total Cash 2 B Total Cash Per Share 9.30 Total Debt 2 B
Total Debt To Equity 49.41 Current Ratio 3.99 Book Value Per Share 21.34
All Measures
Short Ratio 281.00 % Message Board Id finmb_108544 Shares Short Prior Month 5 M
Return On Equity 0.1385 City Marlborough Uuid 1ee39b1d-2fdb-3e89-8451-1d8ac5dfb834
Previous Close 79.00 First Trade Date Epoch Utc 636 M Book Value 21.34
Beta 0.9860 Total Debt 2 B Volume 1 M
Price To Book 3.72 Last Split Date 1 B Fifty Two Week Low 67.59
Total Cash Per Share 9.30 Total Revenue 3 B Shares Short Previous Month Date 1 B
Target Median Price 89.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins 24.36 % Target Mean Price 87.22 Net Income To Common 701 M
Short Percent Of Float 0.0297 Implied Shares Outstanding 232 M Trailing Peg Ratio 128.09 %
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 2 B Next Fiscal Year End 1 B Revenue Per Share 16.71
Held Percent Insiders 0.0079 Ebitda Margins 31.16 % Trailing PE 23.93
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 79.00
Target Low Price 70.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 80.28
Open 79.00 Free Cashflow 757 M State MA
Dividend Yield 0.00 % Return On Assets 0.0645 Time Zone Short Name EST
Trailing Eps 3.32 Day Low 78.70 Address1 250 Campus Drive
Shares Outstanding 226 M Price Hint 2 Target High Price 96.00
Website https://www.hologic.com 52 Week Change 0.1142 Average Volume 1 M
Earnings Quarterly Growth 97.10 % Forward Eps 4.72 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 306.90 % Last Split Factor 2:1
Regular Market Day High 79.69 Is_sp_500 True Profit Margins 17.59 %
Debt To Equity 49.41 Fifty Two Week High 84.67 Day High 79.69
Shares Short 4 M Regular Market Open 79.00 Industry Key medical-instruments-supplies
Earnings Growth 111.60 % Enterprise To Revenue 4.72 Revenue Growth 4.50 %
Shares Percent Shares Out 0.0198 Operating Cashflow 1 B Currency USD
Time Zone Full Name America/New_York Market Cap 18 B Is_nasdaq_100 False
Zip 01752 Quote Type EQUITY Industry Medical Instruments & Supplies
Long Name Hologic, Inc. Regular Market Day Low 78.70 Held Percent Institutions 1.03
Current Price 79.44 Enterprise To Ebitda 15.15 Financial Currency USD
Current Ratio 3.99 Gross Margins 60.58 % Industry Disp Medical Instruments & Supplies
Number Of Analyst Opinions 15 Country United States Float Shares 228 M
Two Hundred Day Average 77.72 Ir Website http://investors.hologic.com/ Enterprise Value 18 B
Price To Sales Trailing12 Months 4.52 Forward PE 16.86 Regular Market Volume 1 M
Ebitda 1 B Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide.

The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products.

In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices.

Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.

It sells its products through direct sales, service forces, independent distributors, and sales representatives.

The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.